Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai, Takeda Rely On U.S. Bioventures To Cover Patent Loss

This article was originally published in PharmAsia News

Executive Summary

At least two major Japanese drug makers are counting on U.S. bioventures to provide them with products they need to replace income now produced by big-selling drugs. Eisai's takeover of MGI Pharma earlier this year gave it new cancer-fighting candidates, giving Eisai entry into an arm of the market considered to have high-growth potential. Takeda's more recent acquisition of Millennium Pharmaceuticals gave it access to cancer and anti-nausea drugs. Although their incomes are relatively small, the U.S. bioventures are expected to defray losses from Japanese drugs about to lose their patent protection. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel